Molecular analysis of cell-free DNA to identify distinct molecular mutational burden and its effect on first-line chemotherapy in patients with NSCLC from a phase III trial
Noninvasive identification of hepatocellular carcinoma mutations in plasma circulating cell-free DNA by targeted deep sequencing.